Targeting VEGFR-2 in breast cancer: synthesis and <i>in silico</i> and <i>in vitro</i> characterization of quinoxaline-based inhibitors
Ibrahim H. Eissa, Alaa Elwan, Mustafa A. Al-Qadhi, Dalal Z. Husein, Fatma G. Amin, Aisha A. Alsfouk, Eslam B. Elkaeed, Hazem Elkady, Ahmed M. Metwaly
Abstract
ADMET analysis predicted a favorable safety profile over sorafenib, particularly with respect to carcinogenic and chronic toxicity risks. These findings indicate that quinoxaline derivative 11d holds potential as a selective and effective VEGFR-2 inhibitor with promising antitumor and anti-metastatic properties, warranting further investigation.
Topics & Concepts
In silicoQuinoxalineIn vitroChemistryMCF-7Breast cancerCancer researchCombinatorial chemistryComputational biologyVEGF receptorsCancerPharmacologyBiochemistryBiologyHuman breastGeneticsOrganic chemistryGeneSynthesis and Biological EvaluationBioactive Compounds and Antitumor AgentsSynthesis and Reactions of Organic Compounds